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Amyotrophic Lateral Sclerosis (ALS) is a chronic, neuromuscular disorder characterized by 
muscle wasting, weakness and spasticity, reflecting a progressive neurodegeneration of 
upper and lower motor-neurons. Selective vulnerability of motor-neurons has been in turn 
ascribed as a consequence of multiple causes: protein misfolding, mitochondrial 
dysfunction, oxidative damage, insufficient growth factor signaling, inflammation and 
glutamate (Glu)-mediated excitotoxicity. High glutamate levels have been reported in ALS 
patients as well as in animal models of the disease and a reduced glutamate transport was 
suggested as a cause. Due to the complex interplay of multiple mechanisms in the 
aetiology of ALS, defects of glutamate transport may not be the only reason for 
excitotoxicity-based neurodegeneration and other causes should be considered for the 
augmented glutamate availability, including increase of glutamate release. To demonstrate 
this hypothesis, we here used mice expressing human SOD1 with the G93A mutation 
[SOD1G93A], a transgenic animal model of human familial ALS, and studied the release of 
glutamate by labeling spinal cord synaptosomes with [3H]D-aspartate, a non metabolizable 
analogue of glutamate. Exposure to 15 mM KCl or 0.3 µM ionomycin provoked Ca2+-
dependent glutamate release that was dramatically increased in SOD1G93A mice. Both 
Glycine and GABA release in spinal cord were not modified. The augmentation of basal 
and stimulated glutamate release was already present in asymptomatic (30-40 day-old) 
and early-symptomatic (60-70 day-old) mutant mice. 
To investigate the molecular mechanisms at the basis of this phenomenon, we studied the 
expression of some synaptic proteins and found that only few of them were changed, 
namely synaptotagmin, actin, myosin and munc-18 in late-symptomatic SOD1G93A mice 
and synaptotagmin and actin only in asymptomatic SOD1G93A mice. Moreover, further 
studies revealed the increased resting and stimulated Ca2+ levels in spinal cord nerve 
terminals from late-symptomatic and asymptomatic SOD1G93A mice, accompanied by 
activation of Ca2+/calmodulin-dependent kinase II (CaMKII) and increased phosphorylation 
of synapsin-I syte 2/3. Also synapsin-I syte 1 and 4/5 were more phosphorilated. Blocking 
synapsin-I phosphorylation normalized the excessive glutamate release in SOD1G93A mice. 
In line with this findings, release experiments supported the involvement of the readily 
releasable pool of vesicles and a greater capability of these vesicles to fuse upon 
stimulation.  
We can conclude that glutamate exocytosis is abnormally elevated not only in late-
symptomatic but also in asymptomatic SOD1G93A mutant mice, suggesting that this 
phenomenon could be a cause and not a conseguence of ALS. Moreover changes in 
cytosolic Ca2+concentrations, auto-activation, synapsin I phosphorylation, augmentation of 
the pool of vesicle docked at the membrane and ready to fuse could represent important 
mechanisms at the basis of the augmented excitatory neurotransmitter release.  
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